Maak een afspraak
- 016 34 59 03.
- In our center, we also offer NIPT for women residing abroad
- NIPT is reimbursed in Belgium from July 1, 2017 onwards.
- The NIPT results can now be consulted in your online medical file through ‘mynexuzhealth’.
Detection in the blood of the mother
NIPT is a non-invasive screening test for the detection of:
- Down syndrome (trisomy 21)
- Edwards syndrome (trisomy 18)
- Patau syndrome (trisomy 13)
Are you considering NIPT for other reasons? You should first discuss this with your doctor. For other specific genetic disorders, an alternative type of genetic testing may be more appropriate.
How does the NIPT work?
- DNA of the baby circulates in small quantities in the blood of the mother.
- In general, sufficient DNA of the baby is present from 10 weeks of gestation onwards.
The NIPT determines:
- Whether or not there is an extra copy of chromosome 21, 18 or 13.
- The sex of the baby.
- Detection via blood sampling in the mother from 10 weeks of gestation onwards.
- No risk for a miscarriage.
- No risk for you or your baby.
- Since November 2013, more than 48,000 analyzes have been completed successfully in our center.
- NIPT has an unprecedented sensitivity of almost 100% for detection of trisomy 21, 18 and 13.
- NIPT is therefore much more reliable than the combined test.
- In less than 1% of the cases, the NIPT result is false positive.
- In this case the test results indicate that the baby has a trisomy, whereas this is not true.
- An abnormal test result should therefore always be confirmed by an invasive test (preferably by amniocentesis).
Rare incidental findings
Using NIPT, all chromosomes are analyzed. Therefore, in rare cases, NIPT can also detect other chromosomal abnormalities, for example:
- A trisomy of a chromosome other than 13, 18 or 21 (frequency: 1/300 of the analyzes performed).
- A chromosome abnormality in the mother that is important for her own health or for that of her baby.
- Some types of cancer in the mother.
In either one of these cases, your doctor will inform you accordingly.
- From the 10th week of gestation onwards.
- If, during this pregnancy, a combined test or NIPT has not already been performed and reimbursed by the public health insurance.
Please provide the following information on the request form for correct interpretation of the test results:
- Monozygotic or dizygotic twin pregnancy or multiple pregnancy (identical and non-identical twins).
- Pregnancy with a ‘vanishing twin’ (original twin pregnancy with one baby deceased early in pregnancy).
- The weight of the mother prior to the pregnancy exceeded 100 kg.
- The mother has (had) cancer.
- The mother has (had) lupus.
- The mother is/was on heparin therapy.
NIPT is not appropriate in case of:
- Ultrasound abnormalities in your baby (including a nuchal translucency of >3.5mm).
- The mother has had one of the following treatments within 3 months prior to the NIPT:
- Blood transfusion
- Stem cell therapy
- Organ transplant
In these cases an invasive test is recommended, such as a chorionic villus sampling or an amniocentesis.
Limitations of NIPT
NIPT is not able to detect:
- Mosaic trisomy 21, 18 or 13 (not all the cells have a trisomy)
- Small chromosome abnormalities (microdeletions or microduplications)
- Monogenic (single gene) disorders (such as cystic fibrosis or fragile X syndrome)
- Numerical abnormalities of the sex chromosomes (such as Turner syndrome or Klinefelter syndrome)
The result will be available within a maximum of 7 calendar days from the receipt of the blood sample in our laboratory.
The results can be consulted in your online medical file through ‘mynexuzhealth’. You will also receive a hard copy of these results. In case of an abnormal result, your doctor or the Centre of Human Genetics will inform you.
Possible test results
- Normal: no indication for the presence of trisomy 21, 18 or 13 in the baby.
- Abnormal: strong suspicion of the presence of trisomy 21, 18 or 13 in the baby.
- To have complete certainty, an abnormal NIPT result should always be confirmed by an invasive test, preferably amniocentesis.
- Inconclusive: the NIPT result cannot exclude nor confirm the presence of trisomy 21, 18 or 13 in the baby. An inconclusive result occurs in less than 1% of the analyzed samples. In this case, further follow-up is recommended, either by a new NIPT analysis on a second blood sample (at no additional cost), or additional ultrasound followed by an invasive test (amniocentesis).
- No result: in less than 0,5% of the cases, the NIPT fails. If this is due to technical issues, the NIPT can be repeated once on a second blood sample (at no additional cost), or you can opt for another test.
- NIPT is reimbursed in Belgium from July 1, 2017 onwards. Hence, pregnant women who are a member of a Belgian service for public health insurance, only pay € 8,68 for the test.
- In case of an increased allowance, the NIPT is free of charge.
- In other cases, your personal cost for the laboratory test is € 260.
- For a genetic consultation, an additional € 12 will be charged if you are a member of a Belgian service for public health insurance, otherwise you will be charged € 37,48.